Seldane (terfenadine) — the Allergy Pill Pulled in 1998 for Deadly Heart Arrhythmias

When Hoechst Marion Roussel pulled Seldane from the U.S. market in 1997 and the Food and Drug Administration formally withdrew its approval effective 4 November 1998, the official posture was prudent stewardship; the documented record shows the company removing a drug it had known to be conditionally lethal for at least six years, and doing so only once it had a patented, profitable substitute ready to sell. Seldane (terfenadine), synthesized by Richardson-Merrell chemists in 1973 and marketed in the United States in 1985 as the world’s first nonsedating antihistamine, was a genuine therapeutic advance: it relieved hay fever without the drowsiness that made older antihistamines hazardous to drivers and workers. That advance concealed a defect in the molecule itself.

The gap between promise and harm lay in pharmacokinetics. Terfenadine as swallowed was a prodrug, almost entirely converted by the liver enzyme CYP3A4 into an active metabolite that did the antihistamine work. The unconverted parent compound, however, blocked the hERG (Kv11.1) cardiac potassium channel, prolonging the QT interval and inviting torsades de pointes, a chaotic ventricular rhythm that can kill within minutes. So long as metabolism was brisk, parent levels stayed trivial and the heart was safe. But any common CYP3A4 inhibitor — the antifungals ketoconazole and itraconazole, the macrolide antibiotics erythromycin and clarithromycin, even a glass of grapefruit juice — could throttle that conversion, let the parent drug pile up, and convert an allergy pill into an arrhythmogen. A patient stable for years could be killed by a course of antibiotics for a sinus infection.

The verdict is therefore plain at the outset: the danger was not a late surprise but a measured, published mechanism. FDA reports flagged ventricular arrhythmias by June 1990; a boxed warning followed in July 1992; and the landmark Honig study in JAMA in March 1993 demonstrated, in healthy volunteers, that ketoconazole co-administration made parent terfenadine accumulate and the QT interval lengthen. For most of the drug’s life the response was a warning label on a product that remained on pharmacy shelves and, for a time, was even pursued for over-the-counter status.

What finally ended Seldane was not the body count but the chemistry of replacement. The active metabolite — fexofenadine — carried the antihistamine benefit without the parent compound’s hERG liability. Marion Merrell Dow’s successor patented it, the FDA approved it as Allegra in July 1996, and only then did the maker withdraw Seldane and the FDA move to revoke approval. Terfenadine became the first blockbuster pulled for QT-related arrhythmia, the case that taught regulators to screen new drugs against the hERG channel, and a byword for a harm that was understood, labeled, and tolerated until a safer money-maker was ready.